The same substance that hampers the infection capability of bacteria can hasten the fiber formation of the protein that is involved in the development of Parkinson’s disease.
The study shows how important basic research is to our understanding of possible side effects from drug candidates interacting with various target proteins.
The study was done by researchers at Umeå University in Sweden and is published in the latest issue of the prestigious Journal of the American Chemical Society. The findings surprise all the researchers involved.
Fredrik Almqvist, professor of organic chemistry, working with colleagues at Washington University in St. Louis and the University of Michigan in Ann Arbor, has developed a molecule, FN075, that slows down the infection capability of bacteria. This molecule blocks the growth and function of the hair-like shoots that bacteria use to cause infections. Even though the molecule is not used in any drugs today, this disarming principle could be of great importance in future struggles against resistance to antibiotics.
The study shows how important basic research is to our understanding of possible side effects from drug candidates interacting with various target proteins.
The study was done by researchers at Umeå University in Sweden and is published in the latest issue of the prestigious Journal of the American Chemical Society. The findings surprise all the researchers involved.
Fredrik Almqvist, professor of organic chemistry, working with colleagues at Washington University in St. Louis and the University of Michigan in Ann Arbor, has developed a molecule, FN075, that slows down the infection capability of bacteria. This molecule blocks the growth and function of the hair-like shoots that bacteria use to cause infections. Even though the molecule is not used in any drugs today, this disarming principle could be of great importance in future struggles against resistance to antibiotics.
